AhR is emerging as a tumor modulator in hematological malignancies, including acute myeloid leukemia (AML), multiple myeloma, chronic lymphocytic leukemia (CLL), and lymphomas, where its precise roles are just beginning to be understood. This evidence concerns the gene AHR and plasma cell myeloma.